JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis

JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis

Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease. The Janus kinase (JAK) has been identified as a target in AD, as it regulates specific inflammatory genes and adaptive immune responses. However, the efficacy of topically applied JAK inhibitors in AD is limited due to the uniq...

Full description

Bibliographic Details
Main Authors: Junchao Wu, Lisha Li, Quangang Zhu, Tingrui Zhang, Fengze Miao, Zhen Cui, Guoqiang Dong, Zongguang Tai, Zhongjian Chen
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Atopic dermatitis
Janus kinase
Degraders
Topical treatment
Inflammatory cytokines
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332224000489

Internet

http://www.sciencedirect.com/science/article/pii/S0753332224000489

Similar Items